Global Intramuscular Drug Delivery Market

Intramuscular Drug Delivery Comprehensive Study by Type (Oral (Swallowed Into The Stomach), Intravenous (Injected Into The Vein), Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin)), Application (Infectious Disease, Oncology, Autoimmune Disease, Allergy, Endocrinology Disorders, Others), Drug (Antibiotics (penicillin G benzathine penicillin, streptomycin.), Biologicals- (immunoglobins, vaccines, and toxoids.), Hormonal agents- (testosterone, medroxyprogesterone.)), End User (Hospital, Clinic) Players and Region - Global Market Outlook to 2030

Intramuscular Drug Delivery Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Intramuscular Drug Delivery
An intramuscular injection is a method of injecting drugs into the muscles. This allows for rapid absorption of the medicine into the bloodstream. Such as the flu shot, people may have received an intramuscular injection at a doctor's office. In rare situations, an intramuscular injection can be self-administered. Certain medications used to treat multiple sclerosis or rheumatoid arthritis, for example, may require self-injection. The intramuscular method is faster than the subcutaneous route in terms of absorption, and muscle tissue can often absorb a higher volume of fluid without causing discomfort. Medication injected into muscle tissues, on the other side, is absorbed more slowly and takes longer to take action than medication administered intravenously.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.4%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Intramuscular Drug Delivery market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Antares Pharma (United States), Pfizer (United States), Johnson & Johnson (United States), Eli Lily (United States), Glaxo SmithKline (United Kingdom), Inovio Pharmaceuticals (United States), Merck (United States), Novartis (Switzerland), Pacira Pharmaceuticals (United States) and Pharmajet (Unite States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Intramuscular Drug Delivery market by Type (Oral (Swallowed Into The Stomach), Intravenous (Injected Into The Vein) and Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin)), Application (Infectious Disease, Oncology, Autoimmune Disease, Allergy, Endocrinology Disorders and Others) and Region.



On the basis of geography, the market of Intramuscular Drug Delivery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Antibiotics (penicillin G benzathine penicillin, streptomycin.) will boost the Intramuscular Drug Delivery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Intramuscular Drug Delivery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growth In Healthcare Infrastructure Across Emerging Regions and Increase The Investment In Artificial Intelligence For Metastatic Ovarian Cancer Drug

Market Growth Drivers:
Increasing Prevalence Of Chronic Diseases and Increasing Demand Of Self-Administered Drug Delivery Injection

Challenges:
IM Delivery Causes The Allergies Depending On The Drug Used And The Patient's Vulnerability To Various Allergens

Restraints:
IM Drug Delivery Absorption Is Relatively Low As Compared To IV Rout

Opportunities:
Rising Investment In Research & Development Costs In The Pharmaceutical Industries and Favorable Government Initiatives

Market Leaders and their expansionary development strategies
In April 2022, Halozyme acquired Antares Pharma to create a specialty leader and drug delivery company. Antares Pharma is a leading specialty pharmaceutical company that manufactures drug delivery solutions. The acquisition will strengthen Halozyme's position in the global drug delivery market.
In February 2021, Biogen's intramuscular injection PLEGRIDY received FDA approval for multiple sclerosis as a treatment option with reduced injection site reactions. With this approval and marketing authorization for the IM administration in European Union Biogen will expand its MS treatments portfolio and offer more options to meet the consumers' needs and preferences.
In 2021, FDA approved CABENUVA for intramuscular use as a complete treatment for adults with HIV-1. According to guidelines initial doses should be a single 600-mg gluteal intramuscular injection of cabotegravir and a single 900-mg gluteal intramuscular injection of rilpivirine after that continuation injection doses will be 400-mg and 600 mg for cabotegravir and rilpivirine respectively.

Key Target Audience
Intramuscular Drug Delivery Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Oral (Swallowed Into The Stomach)
  • Intravenous (Injected Into The Vein)
  • Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin)
By Application
  • Infectious Disease
  • Oncology
  • Autoimmune Disease
  • Allergy
  • Endocrinology Disorders
  • Others
By Drug
  • Antibiotics (penicillin G benzathine penicillin, streptomycin.)
  • Biologicals- (immunoglobins, vaccines, and toxoids.)
  • Hormonal agents- (testosterone, medroxyprogesterone.)

By End User
  • Hospital
  • Clinic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence Of Chronic Diseases
      • 3.2.2. Increasing Demand Of Self-Administered Drug Delivery Injection
    • 3.3. Market Challenges
      • 3.3.1. IM Delivery Causes The Allergies Depending On The Drug Used And The Patient's Vulnerability To Various Allergens
    • 3.4. Market Trends
      • 3.4.1. Growth In Healthcare Infrastructure Across Emerging Regions
      • 3.4.2. Increase The Investment In Artificial Intelligence For Metastatic Ovarian Cancer Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Intramuscular Drug Delivery, by Type, Application, Drug, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Intramuscular Drug Delivery (Value)
      • 5.2.1. Global Intramuscular Drug Delivery by: Type (Value)
        • 5.2.1.1. Oral (Swallowed Into The Stomach)
        • 5.2.1.2. Intravenous (Injected Into The Vein)
        • 5.2.1.3. Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin)
      • 5.2.2. Global Intramuscular Drug Delivery by: Application (Value)
        • 5.2.2.1. Infectious Disease
        • 5.2.2.2. Oncology
        • 5.2.2.3. Autoimmune Disease
        • 5.2.2.4. Allergy
        • 5.2.2.5. Endocrinology Disorders
        • 5.2.2.6. Others
      • 5.2.3. Global Intramuscular Drug Delivery by: Drug (Value)
        • 5.2.3.1. Antibiotics (penicillin G benzathine penicillin, streptomycin.)
        • 5.2.3.2. Biologicals- (immunoglobins, vaccines, and toxoids.)
        • 5.2.3.3. Hormonal agents- (testosterone, medroxyprogesterone.)
      • 5.2.4. Global Intramuscular Drug Delivery by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinic
      • 5.2.5. Global Intramuscular Drug Delivery Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Intramuscular Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Antares Pharma (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lily (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Glaxo SmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Inovio Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pacira Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pharmajet (Unite States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Intramuscular Drug Delivery Sale, by Type, Application, Drug, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Intramuscular Drug Delivery (Value)
      • 7.2.1. Global Intramuscular Drug Delivery by: Type (Value)
        • 7.2.1.1. Oral (Swallowed Into The Stomach)
        • 7.2.1.2. Intravenous (Injected Into The Vein)
        • 7.2.1.3. Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin)
      • 7.2.2. Global Intramuscular Drug Delivery by: Application (Value)
        • 7.2.2.1. Infectious Disease
        • 7.2.2.2. Oncology
        • 7.2.2.3. Autoimmune Disease
        • 7.2.2.4. Allergy
        • 7.2.2.5. Endocrinology Disorders
        • 7.2.2.6. Others
      • 7.2.3. Global Intramuscular Drug Delivery by: Drug (Value)
        • 7.2.3.1. Antibiotics (penicillin G benzathine penicillin, streptomycin.)
        • 7.2.3.2. Biologicals- (immunoglobins, vaccines, and toxoids.)
        • 7.2.3.3. Hormonal agents- (testosterone, medroxyprogesterone.)
      • 7.2.4. Global Intramuscular Drug Delivery by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinic
      • 7.2.5. Global Intramuscular Drug Delivery Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Intramuscular Drug Delivery: by Type(USD Million)
  • Table 2. Intramuscular Drug Delivery Oral (Swallowed Into The Stomach) , by Region USD Million (2018-2023)
  • Table 3. Intramuscular Drug Delivery Intravenous (Injected Into The Vein) , by Region USD Million (2018-2023)
  • Table 4. Intramuscular Drug Delivery Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin) , by Region USD Million (2018-2023)
  • Table 5. Intramuscular Drug Delivery: by Application(USD Million)
  • Table 6. Intramuscular Drug Delivery Infectious Disease , by Region USD Million (2018-2023)
  • Table 7. Intramuscular Drug Delivery Oncology , by Region USD Million (2018-2023)
  • Table 8. Intramuscular Drug Delivery Autoimmune Disease , by Region USD Million (2018-2023)
  • Table 9. Intramuscular Drug Delivery Allergy , by Region USD Million (2018-2023)
  • Table 10. Intramuscular Drug Delivery Endocrinology Disorders , by Region USD Million (2018-2023)
  • Table 11. Intramuscular Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 12. Intramuscular Drug Delivery: by Drug(USD Million)
  • Table 13. Intramuscular Drug Delivery Antibiotics (penicillin G benzathine penicillin, streptomycin.) , by Region USD Million (2018-2023)
  • Table 14. Intramuscular Drug Delivery Biologicals- (immunoglobins, vaccines, and toxoids.) , by Region USD Million (2018-2023)
  • Table 15. Intramuscular Drug Delivery Hormonal agents- (testosterone, medroxyprogesterone.) , by Region USD Million (2018-2023)
  • Table 16. Intramuscular Drug Delivery: by End User(USD Million)
  • Table 17. Intramuscular Drug Delivery Hospital , by Region USD Million (2018-2023)
  • Table 18. Intramuscular Drug Delivery Clinic , by Region USD Million (2018-2023)
  • Table 19. South America Intramuscular Drug Delivery, by Country USD Million (2018-2023)
  • Table 20. South America Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 21. South America Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 22. South America Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 23. South America Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 24. Brazil Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 25. Brazil Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 26. Brazil Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 27. Brazil Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 28. Argentina Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 29. Argentina Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 30. Argentina Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 31. Argentina Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 32. Rest of South America Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 35. Rest of South America Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 36. Asia Pacific Intramuscular Drug Delivery, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 40. Asia Pacific Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 41. China Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 42. China Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 43. China Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 44. China Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 45. Japan Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 46. Japan Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 47. Japan Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 48. Japan Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 49. India Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 50. India Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 51. India Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 52. India Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 53. South Korea Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 54. South Korea Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 55. South Korea Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 56. South Korea Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 57. Taiwan Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 58. Taiwan Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 59. Taiwan Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 60. Taiwan Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 61. Australia Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 62. Australia Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 63. Australia Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 64. Australia Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 69. Europe Intramuscular Drug Delivery, by Country USD Million (2018-2023)
  • Table 70. Europe Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 71. Europe Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 72. Europe Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 73. Europe Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 74. Germany Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 75. Germany Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 76. Germany Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 77. Germany Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 78. France Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 79. France Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 80. France Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 81. France Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 82. Italy Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 83. Italy Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 84. Italy Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 85. Italy Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 86. United Kingdom Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 89. United Kingdom Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 90. Netherlands Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 91. Netherlands Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 92. Netherlands Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 93. Netherlands Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 94. Rest of Europe Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 97. Rest of Europe Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 98. MEA Intramuscular Drug Delivery, by Country USD Million (2018-2023)
  • Table 99. MEA Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 100. MEA Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 101. MEA Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 102. MEA Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 103. Middle East Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 104. Middle East Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 105. Middle East Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 106. Middle East Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 107. Africa Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 108. Africa Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 109. Africa Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 110. Africa Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 111. North America Intramuscular Drug Delivery, by Country USD Million (2018-2023)
  • Table 112. North America Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 113. North America Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 114. North America Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 115. North America Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 116. United States Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 117. United States Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 118. United States Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 119. United States Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 120. Canada Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 121. Canada Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 122. Canada Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 123. Canada Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 124. Mexico Intramuscular Drug Delivery, by Type USD Million (2018-2023)
  • Table 125. Mexico Intramuscular Drug Delivery, by Application USD Million (2018-2023)
  • Table 126. Mexico Intramuscular Drug Delivery, by Drug USD Million (2018-2023)
  • Table 127. Mexico Intramuscular Drug Delivery, by End User USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Intramuscular Drug Delivery: by Type(USD Million)
  • Table 139. Intramuscular Drug Delivery Oral (Swallowed Into The Stomach) , by Region USD Million (2025-2030)
  • Table 140. Intramuscular Drug Delivery Intravenous (Injected Into The Vein) , by Region USD Million (2025-2030)
  • Table 141. Intramuscular Drug Delivery Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of Skin) , by Region USD Million (2025-2030)
  • Table 142. Intramuscular Drug Delivery: by Application(USD Million)
  • Table 143. Intramuscular Drug Delivery Infectious Disease , by Region USD Million (2025-2030)
  • Table 144. Intramuscular Drug Delivery Oncology , by Region USD Million (2025-2030)
  • Table 145. Intramuscular Drug Delivery Autoimmune Disease , by Region USD Million (2025-2030)
  • Table 146. Intramuscular Drug Delivery Allergy , by Region USD Million (2025-2030)
  • Table 147. Intramuscular Drug Delivery Endocrinology Disorders , by Region USD Million (2025-2030)
  • Table 148. Intramuscular Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 149. Intramuscular Drug Delivery: by Drug(USD Million)
  • Table 150. Intramuscular Drug Delivery Antibiotics (penicillin G benzathine penicillin, streptomycin.) , by Region USD Million (2025-2030)
  • Table 151. Intramuscular Drug Delivery Biologicals- (immunoglobins, vaccines, and toxoids.) , by Region USD Million (2025-2030)
  • Table 152. Intramuscular Drug Delivery Hormonal agents- (testosterone, medroxyprogesterone.) , by Region USD Million (2025-2030)
  • Table 153. Intramuscular Drug Delivery: by End User(USD Million)
  • Table 154. Intramuscular Drug Delivery Hospital , by Region USD Million (2025-2030)
  • Table 155. Intramuscular Drug Delivery Clinic , by Region USD Million (2025-2030)
  • Table 156. South America Intramuscular Drug Delivery, by Country USD Million (2025-2030)
  • Table 157. South America Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 158. South America Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 159. South America Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 160. South America Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 161. Brazil Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 162. Brazil Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 163. Brazil Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 164. Brazil Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 165. Argentina Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 166. Argentina Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 167. Argentina Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 168. Argentina Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 169. Rest of South America Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 170. Rest of South America Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 171. Rest of South America Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 172. Rest of South America Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 173. Asia Pacific Intramuscular Drug Delivery, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 175. Asia Pacific Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 176. Asia Pacific Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 177. Asia Pacific Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 178. China Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 179. China Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 180. China Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 181. China Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 182. Japan Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 183. Japan Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 184. Japan Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 185. Japan Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 186. India Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 187. India Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 188. India Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 189. India Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 190. South Korea Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 191. South Korea Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 192. South Korea Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 193. South Korea Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 194. Taiwan Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 195. Taiwan Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 196. Taiwan Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 197. Taiwan Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 198. Australia Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 199. Australia Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 200. Australia Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 201. Australia Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 206. Europe Intramuscular Drug Delivery, by Country USD Million (2025-2030)
  • Table 207. Europe Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 208. Europe Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 209. Europe Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 210. Europe Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 211. Germany Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 212. Germany Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 213. Germany Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 214. Germany Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 215. France Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 216. France Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 217. France Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 218. France Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 219. Italy Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 220. Italy Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 221. Italy Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 222. Italy Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 223. United Kingdom Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 224. United Kingdom Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 225. United Kingdom Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 226. United Kingdom Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 227. Netherlands Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 228. Netherlands Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 229. Netherlands Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 230. Netherlands Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 231. Rest of Europe Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 232. Rest of Europe Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 233. Rest of Europe Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 234. Rest of Europe Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 235. MEA Intramuscular Drug Delivery, by Country USD Million (2025-2030)
  • Table 236. MEA Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 237. MEA Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 238. MEA Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 239. MEA Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 240. Middle East Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 241. Middle East Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 242. Middle East Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 243. Middle East Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 244. Africa Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 245. Africa Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 246. Africa Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 247. Africa Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 248. North America Intramuscular Drug Delivery, by Country USD Million (2025-2030)
  • Table 249. North America Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 250. North America Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 251. North America Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 252. North America Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 253. United States Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 254. United States Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 255. United States Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 256. United States Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 257. Canada Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 258. Canada Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 259. Canada Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 260. Canada Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 261. Mexico Intramuscular Drug Delivery, by Type USD Million (2025-2030)
  • Table 262. Mexico Intramuscular Drug Delivery, by Application USD Million (2025-2030)
  • Table 263. Mexico Intramuscular Drug Delivery, by Drug USD Million (2025-2030)
  • Table 264. Mexico Intramuscular Drug Delivery, by End User USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Intramuscular Drug Delivery: by Type USD Million (2018-2023)
  • Figure 5. Global Intramuscular Drug Delivery: by Application USD Million (2018-2023)
  • Figure 6. Global Intramuscular Drug Delivery: by Drug USD Million (2018-2023)
  • Figure 7. Global Intramuscular Drug Delivery: by End User USD Million (2018-2023)
  • Figure 8. South America Intramuscular Drug Delivery Share (%), by Country
  • Figure 9. Asia Pacific Intramuscular Drug Delivery Share (%), by Country
  • Figure 10. Europe Intramuscular Drug Delivery Share (%), by Country
  • Figure 11. MEA Intramuscular Drug Delivery Share (%), by Country
  • Figure 12. North America Intramuscular Drug Delivery Share (%), by Country
  • Figure 13. Global Intramuscular Drug Delivery share by Players 2023 (%)
  • Figure 14. Global Intramuscular Drug Delivery share by Players (Top 3) 2023(%)
  • Figure 15. Global Intramuscular Drug Delivery share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Antares Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 18. Antares Pharma (United States) Revenue: by Geography 2023
  • Figure 19. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer (United States) Revenue: by Geography 2023
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 23. Eli Lily (United States) Revenue, Net Income and Gross profit
  • Figure 24. Eli Lily (United States) Revenue: by Geography 2023
  • Figure 25. Glaxo SmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Glaxo SmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Inovio Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. Inovio Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 29. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck (United States) Revenue: by Geography 2023
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 33. Pacira Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pacira Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 35. Pharmajet (Unite States) Revenue, Net Income and Gross profit
  • Figure 36. Pharmajet (Unite States) Revenue: by Geography 2023
  • Figure 37. Global Intramuscular Drug Delivery: by Type USD Million (2025-2030)
  • Figure 38. Global Intramuscular Drug Delivery: by Application USD Million (2025-2030)
  • Figure 39. Global Intramuscular Drug Delivery: by Drug USD Million (2025-2030)
  • Figure 40. Global Intramuscular Drug Delivery: by End User USD Million (2025-2030)
  • Figure 41. South America Intramuscular Drug Delivery Share (%), by Country
  • Figure 42. Asia Pacific Intramuscular Drug Delivery Share (%), by Country
  • Figure 43. Europe Intramuscular Drug Delivery Share (%), by Country
  • Figure 44. MEA Intramuscular Drug Delivery Share (%), by Country
  • Figure 45. North America Intramuscular Drug Delivery Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Antares Pharma (United States)
  • Pfizer (United States)
  • Johnson & Johnson (United States)
  • Eli Lily (United States)
  • Glaxo SmithKline (United Kingdom)
  • Inovio Pharmaceuticals (United States)
  • Merck (United States)
  • Novartis (Switzerland)
  • Pacira Pharmaceuticals (United States)
  • Pharmajet (Unite States)
Select User Access Type

Key Highlights of Report


Apr 2024 168 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Intramuscular Drug Delivery Market Quantitative research analysis
Global Intramuscular Drug Delivery Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Antares Pharma (United States), Pfizer (United States), Johnson & Johnson (United States), Eli Lily (United States), Glaxo SmithKline (United Kingdom), Inovio Pharmaceuticals (United States), Merck (United States), Novartis (Switzerland), Pacira Pharmaceuticals (United States) and Pharmajet (Unite States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growth In Healthcare Infrastructure Across Emerging Regions " is seen as one of major influencing trends for Intramuscular Drug Delivery Market during projected period 2023-2030.
The Intramuscular Drug Delivery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Intramuscular Drug Delivery Market Report?

Have a Query? Click Here

Other Related Reports

Ambulatory Healthcare Service Comprehensive Study by Type (Blood Tests, Biopsy, Chemotherapy, Colonoscopy, CT Scan, Mammograms, Minor Surgical Procedures), Application (Outpatient Department, Primary...
$ 3750
Air Medical Services Comprehensive Study by Type (Medical Evacuation, Casualty Evacuation), Application (Civilian, Military), Air Ambulance Type (Helicopter, Aeroplane), Operator Type (Independent, H...
$ 3350
Site Management Organization Comprehensive Study by Type (Trials of Drugs, Trials of Devices, Trials of Procedures), Application (Tumor, Cardiovascular System, Endocrine, Respiration, Anti-infection,...
$ 3500
Sex Reassignment Surgery Comprehensive Study by Gender Transition (Male To Female (Facial, Breast, and Genitals), Female To Male (Facial, Chest, and Genitals)), End-User (Hospitals & Clinics, Others)...
$ 3500
Online Fitness Comprehensive Study by Type (Subscription, Pay by Course), Application (Men, Women), Streaming (Online Programs, Live Streaming), End Users (Gyms, Individuals, Sport Institutes), Devic...
$ 3450
Medical Device Tester Comprehensive Study by Type (Electrical Safety Tester, Leak Tester, Air Quality Analyser, Others), Application (Hospitals, Clinics, Ambulatory Surgical Center, Others), Testing ...
$ 3650